A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
Figure 3
Perturbation analysis of Subject 1, had resistant variants not pre-existed prior to dosing.
The simulation was initialized with resistant variants not pre-existed at 0.4 d before dosing; the duration of 0.4 d was chosen as the minimum duration for the plasma HCV RNA of variants to reach steady-state by time = 0. Legends: diamonds, data; lines, models with no variants present at 0.4 day before dosing. Had variants not pre-existed prior to dosing, HCV RNA rebound is expected to occur at later time.